NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Unresectable stage III non-small cell lung cancer
Date of first enrollment	04/08/2009
Target sample size	39
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : DE-766 INN of investigational material : Nimotuzumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous drip infusion

Outcome(s)

Primary Outcome	Tolerability The proportion of patients who have completed all of the protocol-stipulated treatments
Secondary Outcome	Safety, response rate, progression-free survival , progression-free survival rate, and survival rate NCI-CTC (ver.3.0), RECIST (ver. 1.1)

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	<= 74age old
Gender	Both
Include criteria	Patients with unresectable stage IIIA or IIIB of NSCLC Patients who are judged to be suitable for radical radiotherapy
Exclude criteria	Patients with another active malignancy Patients who have obvious pulmonary fibrosis or interstitial pneumonia by chest CT-scans Patients with severe or uncontrolled complications